Zevra Therapeutics, Inc. Shareholders' Equity
Zevra Therapeutics, Inc. (ZVRA) had Shareholders' Equity of $217.65 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-05
- 2026-06-30: Stockholders' Equity Attributable to Parent $217.65M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $205.80M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $154.66M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $133.16M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $217.65M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $205.80M 10-Q · filed 2026-08-05 | |
| 2025-12-31 | $154.66M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $133.16M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $117.23M 10-Q · filed 2026-08-05 | |
| 2025-03-31 | $41.02M 10-Q · filed 2026-08-05 | |
| 2024-12-31 | $39.67M 10-Q · filed 2026-08-05 | |
| 2024-09-30 | $69.77M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $32.48M 10-Q · filed 2025-11-05 | |
| 2024-03-31 | $48.82M 10-Q · filed 2025-11-05 | |
| 2023-12-31 | $61.86M 10-K · filed 2026-03-09 | |
| 2023-09-30 | $61.52M 10-Q · filed 2024-11-13 | $67.47M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $58.87M 10-Q · filed 2024-11-13 | $68.50M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $59.27M 10-Q · filed 2024-11-13 | $71.40M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $75.12M 10-K · filed 2025-03-12 | $85.81M 10-K · filed 2023-03-07 |
| 2022-09-30 | $93.79M 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $99.23M 10-Q · filed 2023-11-07 | |
| 2022-03-31 | $121.50M 10-Q · filed 2023-11-07 | |
| 2021-12-31 | $101.66M 10-K · filed 2024-04-01 | $127.12M 10-K · filed 2022-03-31 |
| 2021-09-30 | $131.74M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $130.66M 10-Q · filed 2022-11-10 | |
| 2021-03-31 | $84.25M 10-Q · filed 2022-11-10 | |
| 2020-12-31 | -$66.41M 10-K · filed 2023-03-07 | |
| 2020-09-30 | -$62.33M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$62.86M 10-Q · filed 2021-11-10 | |
| 2020-03-31 | -$68.67M 10-Q · filed 2021-11-10 | |
| 2019-12-31 | -$74.46M 10-K · filed 2022-03-31 | |
| 2019-09-30 | -$70.62M 10-Q · filed 2020-10-30 | |
| 2019-06-30 | -$81.55M 10-Q · filed 2020-10-30 | |
| 2019-03-31 | -$74.84M 10-Q · filed 2020-10-30 | |
| 2018-12-31 | -$66.57M 10-K · filed 2021-03-12 | |
| 2018-09-30 | -$95.34M 10-Q · filed 2019-11-14 | |
| 2018-06-30 | -$83.55M 10-Q · filed 2019-11-14 | |
| 2018-03-31 | -$79.68M 10-Q · filed 2019-11-14 | |
| 2017-12-31 | -$57.52M 10-K · filed 2020-02-28 | |
| 2017-09-30 | -$48.10M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | -$39.28M 10-Q · filed 2017-08-10 | |
| 2017-03-31 | -$33.93M 10-Q · filed 2017-05-22 | |
| 2016-12-31 | -$18.70M 10-K · filed 2019-03-01 | |
| 2016-09-30 | -$9.80M 10-Q · filed 2016-11-10 | |
| 2016-06-30 | $333.00K 10-Q · filed 2016-08-11 | |
| 2016-03-31 | -$11.48M 10-Q · filed 2016-05-13 | |
| 2015-12-31 | -$10.12M 10-K · filed 2018-03-30 | |
| 2015-09-30 | -$5.75M 10-Q · filed 2015-11-13 | |
| 2015-06-30 | $3.46M 10-Q · filed 2015-08-14 | |
| 2015-03-31 | -$54.35M 10-Q · filed 2015-05-29 | |
| 2014-12-31 | -$48.51M 10-K · filed 2018-03-30 | |
| 2013-12-31 | -$24.27M 10-K · filed 2017-03-10 | |
| 2012-12-31 | -$19.18M 10-K · filed 2016-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |